Takeda's alogliptin does not increase heart failure risk in type 2 diabetes

10 March 2015

Japan’s largest drugmaker Takeda (TYO: 4502) has published post-hoc analysis of data from the global EXAMINE trial showing that in patients with type 2 diabetes and recent acute coronary syndrome, alogliptin (trade name Vipidia) compared to placebo did not increase the risk of heart failure.

The dipeptidyl peptidase 4 inhibitor compared to placebo had no effect on the extended exploratory post-hoc composite endpoint of cardiovascular death and hospitalized heart failure. Patients with a history of heart failure prior to randomization had a higher risk of heart failure outcomes in EXAMINE.

The risk in the composite of cardiovascular death and hospitalized heart failure was not increased with alogliptin compared to placebo, with 13.9% in alogliptin against 15.7% in placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK